About GH Research
GH Research is a company based in Dublin (Ireland) founded in 2018 by Magnus C Halle and Theis Terwey. GH Research has raised $125 million across 1 funding round from investors including Citadel, RTW Investments and RA Capital. The company has 50 employees as of December 31, 2024. GH Research offers products and services including GH001 and GH002. GH Research operates in a competitive market with competitors including Lykos, Small Pharma and Ketabon, among others.
- Headquarter Dublin, Ireland
- Employees 50 as on 31 Dec, 2024
- Founders Magnus C Halle, Theis Terwey
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gh Research Plc
-
Annual Revenue
Not available
-
Net Profit
-$38.96 M (USD)-9.48as on Dec 31, 2024
-
EBITDA
-$49.93 M (USD)-22.06as on Dec 31, 2024
-
Total Equity Funding
$125 M (USD)
in 1 rounds
-
Latest Funding Round
$125 M (USD), Series B
Apr 12, 2021
-
Investors
Citadel
& 10 more
-
Employee Count
50
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GH Research
GH Research is a publicly listed company on the NASDAQ with ticker symbol GHRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GH Research
GH Research offers a comprehensive portfolio of products and services, including GH001 and GH002.
Pulmonary inhalation therapy for depression treatment
Intravenous administration for neurological disorders
People of GH Research
Unlock access to complete
Unlock access to complete
Scientific Team
7 people
Finance and Accounting
3 people
Co Team
2 people
Accounts Team
1 people
Leadership Team
1 people
Unlock access to complete
Funding Insights of GH Research
GH Research has successfully raised a total of $125M through 1 strategic funding round. The most recent funding activity was a Series B round of $125 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GH Research
GH Research has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, RTW Investments and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Biotech startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for GH Research
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GH Research
Investment portfolio details for GH Research
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GH Research
Detailed financials for GH Research
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gh Research Comparisons
Peer comparison for GH Research
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GH Research
GH Research operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lykos, Small Pharma and Ketabon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics to treat mental health conditions
|
|
| Locked | Locked | Locked |
Psychedelic-based therapeutics for mental health conditions are developed.
|
|
| Locked | Locked | Locked |
Develops innovative therapeutics for treatment-resistant depression.
|
Detailed competitors of GH Research
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gh Research
Complete news archive for GH Research
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GH Research
GH Research was founded in 2018 and raised its 1st funding round 3 years after it was founded.
GH Research is headquartered in Dublin, Ireland.
Theis Terwey is the current CEO of GH Research. They have also founded this company.
GH Research is a funded company, having raised a total of $125M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at GH Research is 50.
GH Research was founded in 2018 and is based in Dublin, Ireland. Focus is placed on the biotechnology sector, where treatments for mental disorders are developed. The pipeline includes GH001, an inhalable 5-MeO-DMT product intended for resistant depression and related conditions, and GH002, an injectable 5-MeO-DMT formulation for mental health applications. Operations center on advancing these candidates through clinical stages.
GH Research's top competitors include Lykos, Small Pharma and Ketabon.
GH Research offers GH001 and GH002.
Yes, GH Research is publicly traded on NASDAQ under the ticker symbol GHRS.
GH Research has 11 investors. Key investors include Citadel, RTW Investments, RA Capital, Verition Fund Management, and BVF Partners.
The ticker symbol of GH Research is GHRS on NASDAQ.